Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological complete response compared with either drug alone. Here, we report data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Sep 2014

Volume: 15

Issue: 10

Affiliations

[1 ] Institut Jules Bordet and Breast European Adjuvant Study Team, Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.

[2 ] Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, UK.

[3 ] Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

[4 ] Istituto Nazionale del Tumori, Milan, Italy; SOLTI Breast Cancer Research Group, Spain.

[5 ] GlaxoSmithKline, Collegeville, PA, USA.

[6 ] Clinic for Gynaecology, Gynaecologic Oncology and Obstetrics and Breast Cancer Centre, HELIOS Klinikum Berlin, Buch, Germany.

[7 ] Sana Klinikum Offenbach, Offenbach, Germany.

[8 ] National Institute of Oncology, Budapest, Hungary.

[9 ] Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK.

[10 ] Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, NSW, Australia.

[11 ] Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.

[12 ] PUC-RS School of Medicine, Porto Alegre, Brazil.

[13 ] Mayo Clinic, Jacksonville, FL, USA.

[14 ] Institut Jules Bordet and Breast European Adjuvant Study Team, Brussels, Belgium.

[15 ] Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

[16 ] Kliniken Essen-Mitte, Essen, Germany.

[17 ] National Taiwan University Hospital, Taipei, Taiwan.

[18 ] Clinique St-Elisabeth, Namur, Belgium.

[19 ] Mackay Memorial Hospital, Taipei, Taiwan.

[20 ] Kashirskoye Shosse, Moscow, Russia.

[21 ] Cancer Institute "Prof Dr Ion Chiricuta", Cluj-Napoca, Romania.

[22 ] Department of Medical Oncology, University of Pretoria, Pretoria, South Africa.

[23 ] Odessa Oncology Centre, Odessa, Ukraine.

[24 ] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Frontier Science and Technology Research Foundation, Boston, MA, USA.

[25 ] University Hospital Kiel, Kiel, Germany.

[26 ] Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Article

Publisher Item ID: S1470-2045(14)70320-1

DOI: 10.1016/S1470-2045(14)70320-1

PubMed ID: 25130998

SO-VID: bfe7473d-3dae-475e-96ff-5d2d7f6226c7

History

Data availability:

Comments

Comment on this article

scite_

Cited by 156

See all cited by

- Version 1